Latest News-CliniExpert

Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer

TAMPA, Fla.--(BUSINESS WIRE) April 15, 2020 -- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucos

FDA Approves Initiation of Humanigen’s Phase III Study of Lenzilumab in COVID-19 Patients

Burlingame, CA, April 15, 2020 -- Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s pro

Alnylam Receives Fast Track Designation for Vutrisiran for the Treatment of the Polyneuropathy of hATTR Amyloidosis

CAMBRIDGE, Mass.-(BUSINESS WIRE)--Apr. 14, 2020 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA)

Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19

BEIJING - April 14, 2020 -- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company has obtained app

Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629

LEXINGTON, Mass.--(BUSINESS WIRE)-Apr. 14, 2020 -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the po

AstraZeneca Initiates CALAVI Clinical Trial with Calquence Against COVID-19

April 14, 2020 -- AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm

Sanofi and GSK to Join Forces in Unprecedented Vaccine Collaboration to Fight COVID-19

PARIS and LONDON – April 14, 2020 -- Sanofi and GSK today announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both compani

Lilly Begins Clinical Testing of Therapies for COVID-19

INDIANAPOLIS, April 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID),

Data on 53 Patients Treated With Investigational Antiviral Remdesivir Through the Compassionate Use Program Published in New England Journal of Medicine

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 10, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a cohort analysis of 53 patients hospitalized with severe complications of COVI

Relief Therapeutics Drug Aviptadil Enters FDA Trial at Thomas Jefferson University Hospital in Philadelphia, to treat COVID-19-Induced Acute Respiratory Distress

Geneva, Switzerland: April 9, 2020 -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” announces that its drug Aviptadil has now entered FDA clinical trials at Thomas Jefferson University Hospital in

Fujifilm Announces the Start of a Phase II Clinical Trial of its Influenza Antiviral Drug “Avigan® Tablet” for COVID-19 Patients in the U.S.

TOKYO, April 9, 2020 -- FUJIFILM Corporation (President: Kenji Sukeno) announces the initiation of a U.S. phase II clinical trial to evaluate the safety and efficacy of its influenza antiviral drug “A

Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury

DUBLIN and SOUTH SAN FRANCISCO, Calif., April 9, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmace